CSIMarket
 
Collegium Pharmaceutical Inc   (NASDAQ: COLL)
 

Collegium Pharmaceutical Inc's Suppliers Performance

COLL's Supply Chain




 
COLL Costs vs Sales of Suppliers Growth Collegium Pharmaceutical Inc recorded an increase in cost of sales by 47.11 % year on year, sequentially cost of sales grew by 481.09 % in Q2.

More on COLL Suppliers



Collegium Pharmaceutical Inc recorded increase in cost of sales by 47.11 % year on year, sequentially cost of sales grew by 481.09 % in Q2.

More on COLL Suppliers




Collegium Pharmaceutical Inc's Comment on Supply Chain


Contract manufacturers must obtain quarterly quotas from the DEA to produce or procure Schedule I or II substances, including methylphenidate for Jornay PM, oxycodone base for Xtampza ER, and tapentadol for Nucynta products. The DEA regulates production quotas, requires special order forms for distribution, mandates suspicious order monitoring systems, and conducts inspections to ensure compliance. Non-compliance may result in penalties, registration refusals, or criminal proceedings. Additionally, individual states regulate the distribution of controlled substances. Federal laws such as the Comprehensive Addiction and Recovery Act (CARA) and the SUPPORT Act address opioid abuse and treatment, influencing the regulation and coverage of opioid medications. The company and its contract manufacturers are subject to these federal and state regulations, as well as healthcare fraud and abuse laws.

Collegium Pharmaceutical Inc's Comment on Supply Chain


Contract manufacturers must obtain quarterly quotas from the DEA to produce or procure Schedule I or II substances, including methylphenidate for Jornay PM, oxycodone base for Xtampza ER, and tapentadol for Nucynta products. The DEA regulates production quotas, requires special order forms for distribution, mandates suspicious order monitoring systems, and conducts inspections to ensure compliance. Non-compliance may result in penalties, registration refusals, or criminal proceedings. Additionally, individual states regulate the distribution of controlled substances. Federal laws such as the Comprehensive Addiction and Recovery Act (CARA) and the SUPPORT Act address opioid abuse and treatment, influencing the regulation and coverage of opioid medications. The company and its contract manufacturers are subject to these federal and state regulations, as well as healthcare fraud and abuse laws.







COLL's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Collegium Pharmaceutical Inc 739.46 751.74 47.92 423
SUBTOTAL 0.00 0.00 0.00 -


Sources: Collegium Pharmaceutical Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Collegium Pharmaceutical Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.